Mauricio Moreno
Concepts (278)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Free Tissue Flaps | 12 | 2024 | 64 | 7.360 |
Why?
| Head and Neck Neoplasms | 10 | 2024 | 273 | 5.310 |
Why?
| Neck Dissection | 6 | 2021 | 31 | 1.880 |
Why?
| Mandibular Reconstruction | 2 | 2023 | 15 | 1.780 |
Why?
| Length of Stay | 4 | 2023 | 621 | 1.730 |
Why?
| Neck | 4 | 2021 | 100 | 1.550 |
Why?
| Laryngectomy | 3 | 2024 | 28 | 1.490 |
Why?
| Retrospective Studies | 25 | 2024 | 6134 | 1.480 |
Why?
| Postoperative Complications | 8 | 2024 | 996 | 1.200 |
Why?
| Middle Aged | 29 | 2024 | 12206 | 1.130 |
Why?
| Salvage Therapy | 2 | 2024 | 139 | 1.100 |
Why?
| Critical Pathways | 3 | 2023 | 39 | 1.030 |
Why?
| Pharyngectomy | 1 | 2024 | 3 | 0.960 |
Why?
| Laryngeal Neoplasms | 1 | 2024 | 42 | 0.920 |
Why?
| Aged | 23 | 2024 | 9405 | 0.920 |
Why?
| Time-to-Treatment | 1 | 2024 | 66 | 0.900 |
Why?
| Operative Time | 1 | 2023 | 73 | 0.890 |
Why?
| Surgery, Computer-Assisted | 1 | 2023 | 56 | 0.870 |
Why?
| Thyroidectomy | 3 | 2021 | 60 | 0.860 |
Why?
| Male | 30 | 2024 | 25399 | 0.850 |
Why?
| Female | 32 | 2024 | 26635 | 0.830 |
Why?
| Head | 2 | 2021 | 73 | 0.830 |
Why?
| Intraoperative Complications | 2 | 2021 | 112 | 0.790 |
Why?
| Intraoperative Care | 1 | 2021 | 54 | 0.780 |
Why?
| Carcinoma, Squamous Cell | 2 | 2022 | 318 | 0.770 |
Why?
| Humans | 45 | 2024 | 50208 | 0.770 |
Why?
| Chylothorax | 1 | 2021 | 15 | 0.760 |
Why?
| Aged, 80 and over | 13 | 2022 | 3154 | 0.750 |
Why?
| Hypotension | 1 | 2021 | 63 | 0.750 |
Why?
| Vasoconstrictor Agents | 1 | 2021 | 84 | 0.740 |
Why?
| Venous Thrombosis | 1 | 2021 | 90 | 0.730 |
Why?
| Morbidity | 1 | 2021 | 134 | 0.720 |
Why?
| Paranasal Sinus Neoplasms | 2 | 2010 | 21 | 0.710 |
Why?
| Naproxen | 1 | 2019 | 7 | 0.700 |
Why?
| Orthognathic Surgical Procedures | 1 | 2019 | 2 | 0.700 |
Why?
| Thyroid Neoplasms | 2 | 2012 | 111 | 0.690 |
Why?
| Mandible | 1 | 2019 | 21 | 0.680 |
Why?
| Reoperation | 1 | 2021 | 454 | 0.670 |
Why?
| Adult | 20 | 2024 | 13324 | 0.660 |
Why?
| Edema | 1 | 2019 | 69 | 0.650 |
Why?
| Health Status Indicators | 1 | 2019 | 83 | 0.640 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 122 | 0.630 |
Why?
| Health Resources | 1 | 2019 | 75 | 0.620 |
Why?
| Academic Medical Centers | 2 | 2019 | 147 | 0.590 |
Why?
| Thigh | 2 | 2015 | 34 | 0.570 |
Why?
| Treatment Outcome | 15 | 2021 | 5155 | 0.560 |
Why?
| Melanoma | 2 | 2010 | 290 | 0.550 |
Why?
| Surgical Flaps | 2 | 2023 | 120 | 0.530 |
Why?
| Patient Discharge | 2 | 2019 | 319 | 0.530 |
Why?
| Radiotherapy, Adjuvant | 4 | 2024 | 61 | 0.520 |
Why?
| Databases, Factual | 2 | 2019 | 657 | 0.500 |
Why?
| Carcinoma, Papillary | 2 | 2012 | 49 | 0.460 |
Why?
| Parathyroidectomy | 2 | 2012 | 45 | 0.460 |
Why?
| Video-Assisted Surgery | 1 | 2013 | 1 | 0.450 |
Why?
| Tissue and Organ Harvesting | 1 | 2013 | 23 | 0.440 |
Why?
| Soft Tissue Injuries | 1 | 2013 | 17 | 0.440 |
Why?
| Neck Injuries | 1 | 2013 | 21 | 0.430 |
Why?
| Endoscopy | 1 | 2013 | 124 | 0.410 |
Why?
| Speech, Esophageal | 1 | 2010 | 1 | 0.380 |
Why?
| Palatal Obturators | 1 | 2010 | 1 | 0.370 |
Why?
| Parathyroid Neoplasms | 1 | 2010 | 26 | 0.370 |
Why?
| Maxilla | 1 | 2010 | 28 | 0.360 |
Why?
| Carcinoma, Merkel Cell | 3 | 2016 | 41 | 0.360 |
Why?
| Nose Neoplasms | 1 | 2010 | 5 | 0.360 |
Why?
| Nasal Mucosa | 1 | 2010 | 19 | 0.350 |
Why?
| Preoperative Care | 1 | 2011 | 166 | 0.340 |
Why?
| Adolescent | 9 | 2019 | 6390 | 0.340 |
Why?
| Adenoma | 1 | 2010 | 110 | 0.330 |
Why?
| Follow-Up Studies | 6 | 2023 | 2190 | 0.330 |
Why?
| Young Adult | 7 | 2019 | 3981 | 0.320 |
Why?
| Deglutition | 2 | 2024 | 42 | 0.320 |
Why?
| Graft Survival | 2 | 2019 | 150 | 0.310 |
Why?
| Neoplasm Recurrence, Local | 3 | 2022 | 613 | 0.300 |
Why?
| Colitis, Ulcerative | 2 | 2018 | 50 | 0.290 |
Why?
| Crohn Disease | 2 | 2018 | 90 | 0.280 |
Why?
| Skin Neoplasms | 3 | 2016 | 492 | 0.250 |
Why?
| Pain, Postoperative | 3 | 2022 | 158 | 0.250 |
Why?
| Comorbidity | 2 | 2019 | 613 | 0.240 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2016 | 77 | 0.240 |
Why?
| Adenocarcinoma | 2 | 2023 | 397 | 0.240 |
Why?
| Prognosis | 3 | 2019 | 1954 | 0.240 |
Why?
| Pharyngeal Diseases | 1 | 2024 | 14 | 0.240 |
Why?
| Cutaneous Fistula | 1 | 2024 | 15 | 0.240 |
Why?
| Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.230 |
Why?
| Fibula | 1 | 2023 | 21 | 0.230 |
Why?
| Adenoma, Pleomorphic | 1 | 2023 | 3 | 0.230 |
Why?
| Salivary Gland Neoplasms | 1 | 2023 | 7 | 0.230 |
Why?
| Carcinoma, Ductal | 1 | 2023 | 9 | 0.230 |
Why?
| Paranasal Sinuses | 1 | 2023 | 18 | 0.230 |
Why?
| Scapula | 1 | 2023 | 19 | 0.220 |
Why?
| Forearm | 1 | 2023 | 32 | 0.220 |
Why?
| Enteral Nutrition | 1 | 2024 | 147 | 0.220 |
Why?
| Sinusitis | 1 | 2023 | 50 | 0.220 |
Why?
| Deglutition Disorders | 1 | 2024 | 77 | 0.220 |
Why?
| Ambulatory Care Facilities | 1 | 2023 | 125 | 0.220 |
Why?
| Tramadol | 1 | 2022 | 30 | 0.210 |
Why?
| Ambulatory Care | 1 | 2023 | 222 | 0.200 |
Why?
| Microsurgery | 1 | 2021 | 30 | 0.200 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 7 | 0.200 |
Why?
| Anastomosis, Surgical | 1 | 2021 | 66 | 0.200 |
Why?
| Gastrointestinal Agents | 2 | 2018 | 33 | 0.190 |
Why?
| Infusions, Intravenous | 1 | 2021 | 213 | 0.190 |
Why?
| Indocyanine Green | 2 | 2011 | 34 | 0.190 |
Why?
| Cohort Studies | 2 | 2019 | 1422 | 0.190 |
Why?
| Drug Administration Schedule | 1 | 2021 | 377 | 0.190 |
Why?
| Robotics | 1 | 2021 | 43 | 0.190 |
Why?
| Laser Therapy | 2 | 2011 | 84 | 0.180 |
Why?
| Reproducibility of Results | 4 | 2023 | 1185 | 0.180 |
Why?
| Odds Ratio | 1 | 2021 | 546 | 0.180 |
Why?
| Prospective Studies | 5 | 2024 | 2379 | 0.170 |
Why?
| Acetaminophen | 1 | 2022 | 283 | 0.170 |
Why?
| Ultrasonography | 2 | 2012 | 437 | 0.170 |
Why?
| Neoplasm Staging | 3 | 2010 | 738 | 0.170 |
Why?
| Analgesics, Opioid | 2 | 2022 | 557 | 0.160 |
Why?
| Combined Modality Therapy | 2 | 2012 | 636 | 0.160 |
Why?
| Drug Monitoring | 1 | 2018 | 78 | 0.160 |
Why?
| Hospital Costs | 1 | 2019 | 72 | 0.160 |
Why?
| Postoperative Care | 1 | 2019 | 102 | 0.150 |
Why?
| Graft Rejection | 1 | 2019 | 168 | 0.150 |
Why?
| Analysis of Variance | 1 | 2019 | 564 | 0.150 |
Why?
| Heart Defects, Congenital | 1 | 2023 | 585 | 0.150 |
Why?
| Patient Readmission | 1 | 2019 | 217 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 225 | 0.140 |
Why?
| Benzoxazoles | 1 | 2016 | 11 | 0.130 |
Why?
| United States | 2 | 2019 | 4874 | 0.130 |
Why?
| Proto-Oncogene Proteins c-myb | 1 | 2015 | 8 | 0.130 |
Why?
| Cell Proliferation | 2 | 2016 | 1013 | 0.120 |
Why?
| Pyrimidines | 1 | 2016 | 193 | 0.120 |
Why?
| Regression Analysis | 2 | 2012 | 395 | 0.120 |
Why?
| Child | 4 | 2018 | 6851 | 0.110 |
Why?
| Nuclear Proteins | 1 | 2015 | 243 | 0.110 |
Why?
| Apoptosis | 2 | 2016 | 1112 | 0.110 |
Why?
| Arkansas | 1 | 2019 | 1985 | 0.110 |
Why?
| Skin Transplantation | 1 | 2013 | 44 | 0.110 |
Why?
| Quality of Life | 1 | 2019 | 839 | 0.110 |
Why?
| Osteocalcin | 1 | 2012 | 43 | 0.100 |
Why?
| Survival | 1 | 2012 | 12 | 0.100 |
Why?
| Equipment Design | 1 | 2013 | 285 | 0.100 |
Why?
| Hyperparathyroidism, Primary | 1 | 2012 | 35 | 0.100 |
Why?
| Recurrence | 2 | 2012 | 662 | 0.100 |
Why?
| Iodine Radioisotopes | 1 | 2012 | 36 | 0.100 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 6 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 8 | 0.100 |
Why?
| Lasers, Dye | 1 | 2011 | 9 | 0.100 |
Why?
| Hospital Mortality | 1 | 2014 | 407 | 0.100 |
Why?
| Decision Support Techniques | 1 | 2012 | 71 | 0.100 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 378 | 0.100 |
Why?
| Photosensitizing Agents | 1 | 2011 | 21 | 0.100 |
Why?
| Thyroid Gland | 2 | 2022 | 73 | 0.100 |
Why?
| Infrared Rays | 1 | 2011 | 25 | 0.100 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 184 | 0.100 |
Why?
| Biopsy, Fine-Needle | 1 | 2012 | 103 | 0.100 |
Why?
| Transcription Factors | 1 | 2015 | 564 | 0.100 |
Why?
| Photochemotherapy | 1 | 2011 | 34 | 0.100 |
Why?
| Fascia | 1 | 2010 | 6 | 0.090 |
Why?
| Parathyroid Hormone | 1 | 2012 | 147 | 0.090 |
Why?
| Lymph Node Excision | 1 | 2012 | 137 | 0.090 |
Why?
| Laser Coagulation | 1 | 2011 | 26 | 0.090 |
Why?
| Coloring Agents | 1 | 2011 | 70 | 0.090 |
Why?
| Tongue Neoplasms | 1 | 2010 | 11 | 0.090 |
Why?
| Carcinoma | 1 | 2012 | 139 | 0.090 |
Why?
| Speech Intelligibility | 1 | 2010 | 15 | 0.090 |
Why?
| Kaplan-Meier Estimate | 1 | 2012 | 465 | 0.090 |
Why?
| Veins | 1 | 2011 | 71 | 0.090 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2011 | 121 | 0.090 |
Why?
| Survival Analysis | 1 | 2012 | 666 | 0.090 |
Why?
| Vascular Diseases | 1 | 2011 | 74 | 0.090 |
Why?
| Disease-Free Survival | 1 | 2011 | 454 | 0.090 |
Why?
| Tracheostomy | 1 | 2010 | 71 | 0.090 |
Why?
| Lymph Nodes | 1 | 2012 | 263 | 0.090 |
Why?
| Quality Indicators, Health Care | 1 | 2010 | 86 | 0.090 |
Why?
| Risk Assessment | 1 | 2014 | 1262 | 0.080 |
Why?
| Predictive Value of Tests | 1 | 2012 | 905 | 0.080 |
Why?
| Guideline Adherence | 1 | 2010 | 133 | 0.080 |
Why?
| Positron-Emission Tomography | 1 | 2010 | 294 | 0.080 |
Why?
| Survival Rate | 1 | 2010 | 901 | 0.080 |
Why?
| Pneumothorax, Artificial | 1 | 2007 | 1 | 0.070 |
Why?
| Models, Biological | 1 | 2011 | 723 | 0.070 |
Why?
| Severity of Illness Index | 3 | 2018 | 951 | 0.070 |
Why?
| Urologic Surgical Procedures | 1 | 2007 | 27 | 0.070 |
Why?
| Disease Progression | 1 | 2010 | 831 | 0.070 |
Why?
| Diaphragm | 1 | 2007 | 31 | 0.070 |
Why?
| Atrioventricular Node | 1 | 2006 | 5 | 0.070 |
Why?
| Tachycardia, Ectopic Atrial | 1 | 2006 | 3 | 0.070 |
Why?
| Cryosurgery | 1 | 2006 | 36 | 0.070 |
Why?
| Pilot Projects | 2 | 2022 | 697 | 0.070 |
Why?
| Azepines | 2 | 2016 | 18 | 0.070 |
Why?
| Risk Factors | 1 | 2014 | 3629 | 0.060 |
Why?
| Pulmonary Veins | 1 | 2005 | 33 | 0.060 |
Why?
| Laparoscopy | 1 | 2007 | 168 | 0.060 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2016 | 212 | 0.060 |
Why?
| Triazoles | 2 | 2016 | 109 | 0.060 |
Why?
| Fluoroscopy | 1 | 2024 | 46 | 0.060 |
Why?
| Video Recording | 1 | 2024 | 80 | 0.060 |
Why?
| Salivary Ducts | 1 | 2023 | 3 | 0.060 |
Why?
| Parotid Gland | 1 | 2023 | 9 | 0.060 |
Why?
| Ubiquitin Thiolesterase | 1 | 2023 | 18 | 0.060 |
Why?
| Facial Bones | 1 | 2023 | 18 | 0.060 |
Why?
| Atrial Fibrillation | 1 | 2005 | 183 | 0.050 |
Why?
| Ibuprofen | 1 | 2022 | 21 | 0.050 |
Why?
| Tumor Suppressor Proteins | 1 | 2023 | 128 | 0.050 |
Why?
| Recurrent Laryngeal Nerve | 1 | 2021 | 13 | 0.050 |
Why?
| Laryngeal Nerves | 1 | 2021 | 16 | 0.050 |
Why?
| Glossectomy | 1 | 2021 | 6 | 0.050 |
Why?
| Tongue | 1 | 2021 | 39 | 0.050 |
Why?
| Arteries | 1 | 2021 | 92 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2023 | 978 | 0.050 |
Why?
| Cell Line, Tumor | 2 | 2015 | 1416 | 0.040 |
Why?
| Mice | 3 | 2016 | 5759 | 0.040 |
Why?
| Pain Management | 1 | 2021 | 162 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 2018 | 193 | 0.040 |
Why?
| Colonoscopy | 1 | 2018 | 92 | 0.040 |
Why?
| Reference Values | 1 | 2018 | 310 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 244 | 0.040 |
Why?
| Tomography, X-Ray Computed | 1 | 2023 | 1161 | 0.040 |
Why?
| Chile | 1 | 2016 | 4 | 0.030 |
Why?
| Immunotherapy | 1 | 2018 | 240 | 0.030 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 2016 | 24 | 0.030 |
Why?
| Digestive System Surgical Procedures | 1 | 2016 | 33 | 0.030 |
Why?
| Age of Onset | 1 | 2016 | 107 | 0.030 |
Why?
| Age Distribution | 1 | 2016 | 168 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2016 | 96 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2016 | 145 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 151 | 0.030 |
Why?
| Mice, SCID | 1 | 2016 | 176 | 0.030 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 17 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| Acetylation | 1 | 2015 | 97 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2016 | 468 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 2015 | 61 | 0.030 |
Why?
| Animals | 3 | 2016 | 13246 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 381 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2016 | 222 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 601 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 595 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2015 | 236 | 0.030 |
Why?
| Chromatin | 1 | 2015 | 152 | 0.030 |
Why?
| Referral and Consultation | 1 | 2016 | 285 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2015 | 166 | 0.030 |
Why?
| Amino Acid Chloromethyl Ketones | 1 | 2013 | 10 | 0.030 |
Why?
| Phagosomes | 1 | 2013 | 19 | 0.030 |
Why?
| Tissue Fixation | 1 | 2013 | 37 | 0.030 |
Why?
| Paraffin Embedding | 1 | 2013 | 53 | 0.030 |
Why?
| Formaldehyde | 1 | 2013 | 52 | 0.030 |
Why?
| Caspases | 1 | 2013 | 104 | 0.030 |
Why?
| Registries | 1 | 2016 | 522 | 0.030 |
Why?
| Protein Binding | 1 | 2015 | 665 | 0.030 |
Why?
| Enzyme Activation | 1 | 2013 | 275 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2015 | 475 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 990 | 0.030 |
Why?
| RNA, Messenger | 1 | 2016 | 1108 | 0.030 |
Why?
| Preoperative Period | 1 | 2012 | 47 | 0.030 |
Why?
| Up-Regulation | 1 | 2013 | 453 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 206 | 0.020 |
Why?
| Administration, Topical | 1 | 2011 | 56 | 0.020 |
Why?
| Postoperative Period | 1 | 2012 | 168 | 0.020 |
Why?
| Hospitalization | 1 | 2016 | 655 | 0.020 |
Why?
| Cell Survival | 1 | 2013 | 602 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2011 | 143 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 828 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 581 | 0.020 |
Why?
| Cancer Care Facilities | 1 | 2010 | 20 | 0.020 |
Why?
| Leg | 1 | 2011 | 122 | 0.020 |
Why?
| Lasers | 1 | 2011 | 123 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 2922 | 0.020 |
Why?
| Biopsy | 1 | 2011 | 590 | 0.020 |
Why?
| Quality Assurance, Health Care | 1 | 2010 | 149 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1378 | 0.020 |
Why?
| Child, Preschool | 1 | 2016 | 3883 | 0.020 |
Why?
| Carbon Dioxide | 1 | 2007 | 94 | 0.020 |
Why?
| Secondary Prevention | 1 | 2006 | 78 | 0.020 |
Why?
| Atrial Function | 1 | 2005 | 6 | 0.020 |
Why?
| Electrocardiography, Ambulatory | 1 | 2005 | 23 | 0.020 |
Why?
| Angiography | 1 | 2005 | 130 | 0.020 |
Why?
| Heart Rate | 1 | 2006 | 298 | 0.020 |
Why?
| Electrocardiography | 1 | 2006 | 262 | 0.010 |
Why?
| Catheter Ablation | 1 | 2005 | 123 | 0.010 |
Why?
| Logistic Models | 1 | 2005 | 889 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|